Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Agilent Names DePinho Thought Leader and More


Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Ronald DePinho, an oncologist at the University of Texas MD Anderson Cancer Center.

The award provides funds for personnel and an Agilent 6550 iFunnel Q-TOF LC/MS system to support research. DePinho and his team are seeking to discover and characterize alterations in metabolic flux during tumor initiation and maintenance and to identify biomarkers for detecting pancreatic cancer.

Aushon Biosystems said this week it has appointed Thomas Mac Mahon to its board of directors.

Mac Mahon is a presiding director of Aristotle Holding and Express Scripts and was chairman of Laboratory Corporation of America from 1996 to 2009 and CEO and president from 1997 to 2006. Before that he was senior vice president at Hoffmann-La Roche and president of Roche Diagnostics.

Definiens has appointed Ralf Huss to be chief medical officer.

Huss has 20 years of training and experience in histopathology and cancer research, including serving as global head of histopathology and tissue biomarker at Roche Diagnostics, and he co-founded the biotech company APCETH.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.